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Maurizio Perazzolo, Andrea Tapparo,* and Paolo Zattal
Aluminum lactate [Al(lact)31 (hydrophilic, hydrolytically unstable) and aluminum acetylacetonate [Al(acac)3]
(lipophilic, hydrolytically stable) were tested as potential toxicants to rabbits upon IV administration both as
aqueous solutions and as liposome suspensions. Both chemicals behaved as cardiotoxic agents when administered
as aqueous solutions, butAl(acac)3 was atleasttwoordersofmagnitude more active thanAl(lact)3. Al (acac)3,
but not Al(lact)3, caused myocardial infarcts resembling those in humans (with contraction bands) at doses
as low as 0.24 mg/kg body weight, as well as a prominent acanthocytosis. Al(lact)3, when administered as a
liposome suspension, was about300 times more toxic than in aqueous solution, although cardiac damage was
not infarctual in character. Both chemical and physical speciation of aluminum(III) thus play an essential
role in determining the toxicity of the metal.
Introduction
AluminumaII) is being actively investigated as a metal rele-
vant to neurological disorders, such as Alzheimer's disease
(1,2), dialysis dementia (3), osteomalacia (4), as well as being
investigated for ecotoxicological effects (5). A possible role of
aluminum uptake in the pathophysiology ofdementias is sug-
gested from recent epidemiological literature (7). However,
from a biochemical point ofview, the etiological connection
between aluminum(llI) and suchpathologies remains an open
question (1).
In spite of toxicological (in vivo and in vitro) (6), enzy-
mological (8), and biochemical (6,9) work over the last
decade, information on the reactivity ofaluminum(III) with
Lewis bases suitable for mimicking possible interaction(s)
of the metal with receptor sites of biomolecules is scarce
(10,11). Moreover, while considerable information is available
on the metallo-organic chemistry ofaluminum(III) (12), the
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aqueous chemistry of the ion in the presence of organic
ligands at neutral pH is relatively unexplored. Virtually all
biological work, thus, depends on the use ofaqueous solu-
tions in which the chemical identity (the speciation) of the
employed toxin is rather ill-defined. Three main types of
aqueous aluminum have been used so far: a) salts ofstrong
acids (e.g., chloride and sulfate); b) salts ofmoderately strong
acid with appreciable metalbonding ability (e.g., lactate and
tartrate); and c) hydrolytically stable neutral complexes, i.e.,
aluminum acetylacetonate [Al(acac)3] (acetylacetonate=
2,4-pentane-dionate) and aluminum maltolate [Al(malt)3]
(maltolate = 3-hydroxy,2-methyl,4-pyronate).
Solutions oftype a, once adjusted to pH 7.5, produce quan-
titatively Al(OH)3 (solubility equal to about 10-7 M).
Among solutions of type b, those obtained from aluminum
lactate appear to be stable at pH 7.5, but they are, in fact,
probably metastable (13). In this case, the actual identity
ofbiologically active species is a matter ofspeculation (10).
Solutions of type c are currently in use in our laboratory
and in other laboratories (1,14); preliminary results obtained
with Al(acac)3 (14) seem to indicate novel biological effects
of this metal.
We report here on the first extensive toxicological work
carried out with aluminum(llI) solutions in which the nature
of the administered toxin is either well known, i.e.,
Al(acac)3, or at least can be reasonably proposed on the
basis of preliminary new findings (15), i.e., aluminum lac-
tate [Al(lact)3] (lactate=2-hydroxy-propanoate). Data refer-
ring to the use of liposomes as carriers of both Al(acac)3
and AI(lact)3 are also reported.BOMBI ET AL.
Materials and Methods
Animals and Chemicals
New Zealand white adult rabbits were obtained from
Morini (Modena, Italy). Animals were maintained at con-
trolled temperature and humidity and were supplied with
water and standard rabbit food (Italiana Mangimi, Milano,
Italy) adlibitum. The animals were anesthetized with Ketalar
(Parke Davis) before being killed.
Al(lact)3, (Fluka) and DL-dipalmitoylphosphatidylcholine
(DPPC) (Sigma) were of reageant grade and used without
further purification. Al(acac)3 was prepared according to
Yung and Reynolds (16) and was recrystallized from benzene/
light petroleum. The purity of Al(lact)3 and Al(acac)3 was
checked by elemental analysis. Al(acac)3 was further con-
trolled by 1H-NMR and IR spectrometry. Acetylacetone
(2,4-pentanedione) (Janssen) was distilled before use. Ultra-
pure water was prepared by distillation in a fused silica sub-
boiling still and stored in polyethylene bottles. Reagent-grade
concentrated nitric acid (Prolabo) was distilled in a sub-boiling
still and stored in polytetrfluoroethylene (PTFE) bottles.
Diluted nitric acid (1 M) was prepared by weight in a PTFE
bottle.
Preparation and Analysis of Liposome
Suspensions of Al(acac)3
DPPC, 15 mg, and 105 mg of Al(acac)3 (about 0.32
mmole) were dissolved in 2.1 mL ofethanol (95%) at 70°C
with stirring. The resulting solution was slowly injected by
means of a 50-FL microsyringe into a sterile NaCl solution
(9 g/L, 30 mL) at 55 to 60°C. Each 50-FL portion was in-
jected in 10 to 15 sec; during injections, the solution was
stirred and the syringe needle was kept about 1 cm below
the surface. The solution was allowed to cool under stir-
ring and excess DPPC and Al(acac)3 were removed by
dialysis (cellulose membrane, 0 = 1 cm, average pore dia-
meter = 24 A, exclusion limit 8000 to 15000 D, three treat-
ments with 250 mL of physiological solution for 12 hr at
50 C). The final pH was about 7.0; the product had an opal-
escent appearance and was stored at 50C in glass vials.
Monolayer and single compartment characteristics of the
liposomes were checked by a turbidimetric method (17) and
confirmed by electron transmission micrography (18). The
liposomes were found to be stable for about 1 month (turbidi-
metric test) (17).
The total aluminum content ofthe liposome suspensions
was determined as follows: 0.5 mL of the suspension plus
1.0 mL ofwater were acidified with 0.2 mL ofconcentrated
HNO3 and kept at 800C for 1 hr. The pH was adjusted at
7.4 by addition of 0.6 mL of aqueous NH3 (25% w/w) and
of 5 mL ofborate buffer (0.18 M boric acid, 5 mM sodium
tetraborate, pH 7.4). Aluminum was then determined spec-
trophotometrically as the 8-hydroxyquinolinate complex after
extraction with toluene (19).
The aluminum content ofthe liposomes was determined
as follows: 0.5 mL aliquots of the suspension were centri-
fuged (15 min at30,000 rpm) to remove the aqueous phase,
and the organic residual was treated with 1.5 mL of water
and 0.2 mL of concentrated HNO3; the resulting solution
was analyzed as described above. The aluminum content
of the liposomes was found to be about 50% of the total.
Preparation and Analysis of Liposome
Suspensions of Al(lact)3
The procedure and molar amounts were the same as for
Al(acac)3, with the exception that Al(lact)3 was dissolved
in the physiological solution to give a 0.05 M concentration;
the alcoholic solution contained only DPPC.
As most ofthe aluminum was expected to be in the exter-
nal aqueous phase, the dialysis procedure was modified as
follows. During dialysis, the external solution was contin-
uously renewed by a peristaltic pump operating at about 35
mL/hr; the external solution was sampled at various times;
and its aluminum content determined by ionic chromatog-
raphy. A bell-shaped concentration versus time profile was
obtained, with the aluminum concentration dropping to neg-
ligible values (0.4-0.5/AM) after 5 days. The total aluminum
content of the dialyzed suspensions was determined as
described above; in view of the exhaustive nature of the
dialysis procedure, the administered aluminum was assumed
to be essentially all liposomes associated.
Administration Protocol, Chemoclinical
Analyses, and Autoptical and
Histological Evaluation
Animals were injected IV from the rostral auricolar vein
under sterilite conditions. Solutions ofAlOact)3 and AI(acac)3
were sterilized by autoclaving at 1100 C for 15 min. Control
experiments were performed on three rabbits by injection
ofcomparable amounts offree acetylacetone (aqueous solu-
tion, 300 Ag/day for 16 days).
Urea, glucose, creatinine, total cholesterol, total bilirubin,
alanine aminotransferase (ALAT/ GPT), aspartate amino-
transferase (ASAT/GOT), alkaline phosphatase, gamma-
glutamyltransferase (GGT), lactic dehydrogenase (LDH),
creatine kinase (CK), total protein, and triglycerides were
determined by means of Boehringer kits.
Athorough autoptical examination was performed on most
animals. All macroscopic lesions were noted and samples
of brain, spinal cord, heart, lungs, liver, spleen, kidneys,
and skeletal muscle were examined microscopically after24
to 48 hr fixation in 10% buffered formalin. Sections were
stained with hematoxylin-eosin; brain and spinal cord were
also examined with Bodian's stain; heart was examined with
the Alcian-PAS and van Gieson methods.
Decontamination of Analytical Equipment
All the vessels employed for aluminum determination in
tissues were decontaminated by washing with a detergent
and then with diluted nitric acid and were kept immersed
in diluted nitric acid. Fused silica test tubes were boiled in
concentrated nitric acid for 1 hr. All the above items were
carefully rinsed with ultrapure waterbefore use and allowed
to dry in a dust-protectedbox. Micropipette tips were decon-
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taminated before use by loading twice with concentrated
nitric acid and then with water.
Aluminum Determination in Tissues
Organs removed during the autoptic examination were
stored at -20°C in decontaminated polystyrene vessels.
A weighed tissue portion (2-5 g) was homogenized in a
homemade PTFE potter (10 mL capacity) with 1 to 2 mL
ofwater. The homogenate was thentransferred to a decon-
taminated polypropylene test tube, freeze-dried, and stored
at room temperature. The samples were dry ashed accord-
ing to the following procedure (20): 150 to 300 mg of lyo-
philized materialwas directly weighedinto a decontaminated
5-mL fused silica test tube and heated in a muffle furnace
(temperature program: 1.5 hr each at 100, 150, 200, and
2500C; overnight at 4800C). After cooling, 1 mL of 1 M
nitric acid was added, and the test tube was heated at
approximately 1000C for 30 min. Occasionally, after this
treatment, samples were found to contain small amounts
of carbonaceous residue; in this case, the samples were
treated in an ultrasonic bath for 1 hr and heated again as
above. The samples were finally diluted with 1 mL ofwater
and centrifuged. Aluminum was determined in the resulting
clear solution byion chromatography with colorimetric detec-
tion (Fig. 1), using the operating conditions shown in Table 1.
Results and Discussion
Chemical Nature of Al(lact)3 and Al(acac)3
in Water
Aluminumlactate has beenfrequently employed in toxicol-
ogical research to prepare stock solutions of A3l ions. In
1
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FIGURE 1. Detection system employed in the determination of aluminum by
ion-chromatography. (1) Effluent fromthe analytical column; (2) buffer; (3)
chromogenic agent; (4) peristaltic pump; (5) damper; (6) reactor coil; (7)
colorimetric detector.
Table 1. Experimental details in the determination of
aluminum by ion chromatography.
Eluent 0.15 M ammonium sulfate + 0.30 M
ammonium nitrate + 0.10 M nitric acid;
flow rate 0.70 mL/min
Chromogenic reagent 2 mM pyrocatechol violet + 8.8 mM nitric
acid; flow rate 0.35 mL/min
Buffer 3.2 M hexamethylenetetramine + 44.0
mM nitric acid; flow rate 0.35 mL/min
Sampling loop volume 50 ,uL
Detector wavelength 570 nm
fact, this compound is reported to be "freely soluble in
water" (21) and, unlike simple inorganic salts of All", does
not give rise to aluminum hydroxide precipitation upon neu-
tralization and dilution. This observation is in contradiction
with thermodynamic expectations based on a recent poten-
tiometric investigation of the AlF/H20/lact- system (13).
In the pH range 3 to 5, the species [Al(lact)H20)4]2+,
[Al(lact)2(H20)2]+, [Al(lact)2(OH)(H20)], and [Al(lact)3]
have been identified; the relevant stability constants clearly
indicate that at physiological pH values, the total concentra-
tion of Al' in equilibrium with solid Al(OH)3 is unaffected
by the presence of lactate.
The apparent contradiction between thermodynamic
prediction and experimental fact can be explained either by
the existence, at pH 7, ofother, yet unknown, coordination
compounds under equilibrium conditions, or the operation
of kinetic factors. This latter kind of behavior is not unex-
pected for All" complexes under nonacidic conditions (12).
Indeed, no aluminum-lactate complexes exist in appreciable
amount at pH 7.5; rather, the predominant species are aquo-
hydroxo aluminum species, metastable toward Al(OH)3 for-
mation (15). Based on available thermodynamic data (22),
aqueous solutions of Al(acac)3 should be stable at the con-
centration levels employed inthis work. This was confirmed
by the stability with time of the electronic spectra of the
solutions.
lbxicity Data
A comparison of toxicity between aluminum lactate in
aqueous solution (Al(lact)3, aq) and the same chemical car-
ried by liposomes (Al(lact)3, ip) revealed that the latter is
strongly (atleast300 times) more cardiotoxic thanthe former
(Tables 2 and 3). For example, the data for animals 30 and
31 (Al(lact)3, p) and 18 and 19 (Al(lact)3,aq) show that similar
CK figures were reached with analytical amounts ofadmin-
istered toxin that differ by about two orders of magnitude.
This prominent enhancement of toxicity for Al' carried by
the liposomes in their internal water micropools can be
attributed to a biophysical speciation effect.
A liposome-based administration (likely to offer a more
bioavailable form ofAl"') allows for discrimination between
specific cardiotoxic effects of the metal and the rather
nonspecific ones caused by the same species at far greater
concentrations to brain, liver, kidneys, and lungs (Table 2).
In particular, such effects appear to be prominent at
Al(lact)3 doses greater than 70 mg/kg body weight. Under
these conditions, such massive effects could have led to
secondary myocardial damage (e.g., edema).
The biological effect ofAl(acac)3,aq, estimated in terms of
cardiotoxicity (Table 4), was also much higher (about 100
times) than that exhibited by Al(lact)3,aq, but the type of
cardiac damage was quite different. Al(acac)3,aq produced a
myocardial effect, with myocardial necrosis (infarct), pro-
minent contraction bands, and multifocal myocarditis (the
protonated free ligand, acetylacetone, is nontoxic). A 4- to
5-fold increase of aluminum concentration in the cardiac
tissue paralleled the histopathological and chemoclinical data.
Details ofthis experimentally induced pathology have been
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Table 2. Effects of Al(lact)3 (aqueous solution).a
Rabbit Total amount Time of Chemoclinical Al concentration
no.b of Al, mgc deathd Histopathological findings data in tissues, ppml
9 139 30 Brain: no lesions NDf Cortex: 2.2
(10 d, 7 i) (killed) Heart: dilated ventricles; focal round-cell Cerebellum: 4.2
inflammation Thalamo-mesencephalon: 1:1
Liver: focal round-cell and leukocytes Liver: 82
(eosinophils) inflammatory infiltrate Kidneys: 20
in lobular and portal tracts Heart: 9.2
Kidneys: interstitial nephritis
Lungs: acute stasis
13 240 0 Heart: massive dilatation, particularly of the ND ND
(15 d, 12 i) right ventricle; interstitial edema and
myocardial fiber disarray
Liver: massive centrilobular necrosis with
megakaryocytes and erythroblasts
Kidneys: severe glomerulopathy with fibrin
and basophilic granular material in
capillaries; tubular necrosis; extramedullary
hematopoiesis
14 350 0 Brain: no lesions ND ND
(10 d, 5 i) Heart and liver: as for rabbit no. 13
16 328 0 ND ND
(7 d, 4 i)
18 130 2 Brain and heart: as for rabbit no. 9 CV: increase up to ND
(30 d, 21 i) (killed) 530-890 U.I.; other
indexes normal
19 88 2 CK: increase up to ND
(15 d, 11 i) (killed) 570-800 U.I.; other
indexes normal
apH adjusted to 7.5 with NaOH; injected volumes: from 0.5 to 2 mL of - 0.5 M solution.
bNumbers refer to pound registry.
cNumber of days of treatment (d) and number of injections (i) in parentheses.
dNumber of days after the last injection.
eAverage Al concentration, ppm, in controls: total brain, 0.31 ± 0.1; cortex, 0.16 + 0.03; cerebellum, 0.32 + 0.12; thalamo-mesencephalon, 0.29 ± 0.14;
heart, 0.61 ± 0.26; liver, 0.26 ± 0.03; kidney, 0.54 ± 0.25.
'ND, not determined.
9CK, creatine kinase. Normal CK value: 330 ± 76 Ul. (23).
Table 3. Effects of Al(lact)3 (liposome suspension).a
Rabbit no.b Total amount of Al, mgc Time of deathd Histopathological findings Chemoclinical data
30 0.27 2 Heart: interstitial hyperplasia and CKe: gradual
(50 d, 42 i) (killed) fibroblastic proliferation increase up to
Brain, liver, kidneys, spleen, lungs and - 1000 U.I. at
skeletal muscles: no lesions the end of
treatment
31 0.02 2 Heart, brain, liver, kidneys, spleen, Asforrabbitno. 30
(7 d, 4 i) (killed) lungs, and skeletal muscles: as for
rabbit no. 30
Spinal cord: large infarction of the lumbar
tract, probably from ischemic damage
34 0.07 2 Heart, liver, kidneys, lungs, and skeletal CK and LDH:
(15 d, 11 i) (killed) muscles: as for rabbit no. 30 slight irregular
Spinal cord: as for rabbit no. 31 increase
apH 7 (spontaneously reached after dialysis); injected volumes: 4 mL of a 0.06 mM suspension.
'Numbers refer to pound registry.
cTotal amount, including aqueous and liposome carried All" (see text). Number of days of treatment (d) and number of injections (i) in parentheses.
dNumber of days after the last injection.
'CK, pyruvate kinase; LDH, lactate dehydrogenase.
reported (14). It is worth noting that skeletal muscles
undergo only indirect (secondary) damages.
The quite different biological effects on the same organ
observed in the two cases clearly points to the importance
ofthe speciation (i.e., the nature ofthe coordination sphere)
of the administered metal. Cardiac muscle appears to be
a target organ for aluminum (under pathologic conditions)
foruremic patients (3). Itis apparent that the chemical pro-
perties acquired by aluminum(III) in its peculiar speciation
as Al(acac)3 (hydrolytic stability, resistance to scavenging,
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Table 4. Effects of Al(acac)3 (aqueous solution).a
Rabbit Total amount Time of Chemoclinical Al concentration
no.b of Al, mgc deathd Histopathological findings data in tissues, ppml
26 0.8
(13 d, 8 i)
27 0.7
(13 d, 7 i)
35 0.7
(20 d, 15 i)
36 0.7
(20 d, 15 i)
37 0.7
(20 d, 15 i)
0 Brain: no lesions
Heart: dilatation, particularly of the right
ventricle; multifocal degeneration of
myocardial fibers, with myocytolysis and
contraction bands; interstitial edema and
inflammation
Liver: massive stasis, with centrilobular
necrosis
Kidneys: stasis; some eosinophils in
glomerular capillaries
Lungs: acute stasis and edema
Skeletal muscles: no lesions
0 As for rabbit no. 26
0 As for rabbit no. 26
2 As for rabbit no. 26
0 As for rabbit no. 26
38 0.7 1 Brain, heart, liver, kidneys as for rabbit
(20 d, 15 i) (klled) no. 26
39 0.7 50 Brain: no lesions
(20 d, 15 i) (killed) Heart: focal fibrous scars, with some
calcified cells
Blood: development of acanthocytes
40 0.7
(20 d, 15 i)
20 Brain, heart, and blood as for rabbit no. 39
CKf: regular increase up ND9
to 1650 U.I. (after
eight injections)
LDH: slight and irregular
increase
As for rabbit no. 26
CK: irregular increase up
to - 1000 U.I. after
each injection
LDH: slight and irregular
decrease
As for rabbit no. 35
As for rabbit no. 35
As for rabbit no. 35
CK: as for rabbit no. 35;
gradual return to the
normal figure upon
stopping the treatmenth
LDH: as for rabbit no.
35; gradual return to
the normal figure upon
stopping the treatment
As for rabbit no. 39
ND
Brain: 0.31
Heart: 1.7
Liver: 1.6
Kidney: 1.6
Brain: 0.6
Heart: 2.1
Liver: 2.2
Kidney: 1.0
Cortex: 0.08
Cerebellum: 0.79
Thalamo-mesencephalon: 0.18
Heart: 1.3
Liver: 1.9
Kidney: 1.0
Cortex: 0.28
Cerebellum: 0.26
Thalamo-mesencephalon: 0.33
Heart: 1.45
Liver: 2.4
Kidney: 1.1
ND
Cortex: -0.08
Cerebellum: 0.44
Thalamo-mesencephalon: 0.16
Heart: 1.8
Liver: 2.6
Kidney: 0.53
apH 7; injected volumes from 0.5 to 1.5 mL of a
- 2.5 mN Al(acac)3 solution.
bNumbers refer to pound registry.
cNumber of days of treatment (d) and number of injections (i) in parentheses.
dNumber of days after the last injection.
eAverage Alconcentration, ppm, in controls: total brain, 0.31 ± 0.1; cortex, 0.16 ± 0.03; cerebellum, 0.32 ± 0.12; thalamo-mesencephalon, 0.29 ± 0.14;
heart, 0.61 ± 0.26; liver, 0.26 ± 0.03; kidney, 0.54 0.25.
fCK, creatine kinase; LDH, lactate dehydrogenase.
9ND, not determined.
'Normal CK value: 330 ± 76 U.I. (23).
andlipophflicity) (24) facilitate the action ofthis artificial toxin
not only in reaching the organ, but also in interfering with
receptor(s) that are essential to myocardial cell function (14).
The similarity of the cardiotoxic effect ofAl(acac)3,aq and
Al(acac)3,r, (Table 5) might seem surprising, in that a possi-
ble synergic action ofthe lipophilic vehicle with the lipophilic
character of the coordination sphere could have been
expected. Evidently, the above-mentioned properties of
Al(acac)3 make this complex sufficiently well sulted in itself
for selectively producing an infarctual cardiac lesion, such
that the liposomal vehicle does not provide a significant
synergic contribuution. The appreciable accumulation of
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Table 5. Effects of Al(acac)3 (liposome suspension).a
Rabbit no.b Total amount of Al, mgc Time of deathd Histopathological findings Chemoclinical data
5-8 0.8 0 Heart: dilatation, particularly of the NDe
(10-15 d, 7-10 i) right ventricle; multifocal
myocytolysis; interstitial edema and
inflammation
Liver: stasis and mild steatosis
Kidneys: stasis; some eosinophils in
glomerular capillaries
Spleen: congestion
22 0.6 2 As for rabbits nos. 5-8 CKf: 2-fold increase
(20 d, 15 i) (Idled) LDH: 3-fold increase
at the end of
treatment
23 0.6 2 As for rabbits nos. 5-8 CK: 10-fold increase
(20 d, 15 i) (Iled) LDH: 5-fold increase
at the end of
treatment
apH 7; injected volumes from 0.5 to 1.5 mL of a - 3 mM Al(acac)3.
bNumbers refer to pound registry.
cTotal amount injected, including aqueous andliposome carried Al' (see text). Number ofdays of treatment (d) and number ofinjections (i) in parentheses.
dNumber of days after the last injection.
eND, not determined.
fCK, creatine ldnase; LDH, lactate dehydrogenase.
aluminum in liver and kidney (Tables 2 and 4) is not sur-
prising, in view of the specific detoxicating functions car-
ried out by these organs.
Inspection ofTable 4 reveals that rabbit 39 survived after
treatment for 20 days with AI(acac)3,aq. In order to confirm
the irreversible character ofthe artificial myocardial infarct
induced by Al(acac)3 (14), the animal was monitored for an
additional 50 days. Although CK and.LDH indexes returned
to normal values after 3 days, histopathological analysis
revealed that infarcted myocardial areas had undergone
substitution ofthe affected fibers by collagen-rich scartissue
(Fig. 2). A similar pattern was observed also for rabbit 40,
which died spontaneously 20 days after the end oftreatment.
Interestingly, microscopic (SEM) observations on blood
samples from animals 39 and 40 seven days after termina-
FIGURE 2. A collagen-rich tissue scarreplacing afonnerlyinfrcted myocardial
area. van Gieson staining; x 750. (The dark areas correspond to the red
ones in van Gieson staining.)
tion oftreatment revealed amarked morphologicalanomaly
ofthe erythrocytes (acanthocytosis) (Fig. 3). This anomaly,
which was reported as associated with a form ofencephal-
opathy in humans (25), may be interpreted as the conse-
quence either of a damage to the emathopoietic system or
of a direct action of All" on the erythrocyte membrane
(9,26). An in vitro investigation appears to support this latter
hypothesis (27).
As to the effect of Al(lact)3 on the central nervous sys-
tem, this toxin was ratherineffective inproducing appreciable
damage when administered as an aqueous solution, in con-
trast with the observed conspicuous metal accumulation in
the brain (Table 2). On the contrary, treatment with lipo-
some-carried Al(lact)3 gave, in two cases (Table 3), pos-
teriorparaplegia with awide infarcted area inthe spinal cord.
FIGURE 3. Scanning electron microphotograph of erythrocytes from rabbits
treated with Al(acac)3.
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No neurological effects were observed with Al(acac)3.
In general terms, the data reported here do not seem
to indicate any connection between the IV injection of
hydrolytically stable (lipophilic) Al(acac)3 or of hydrolytically
(meta)stable (hydrophilic) Al(lact)3 and neurological
disorders. The appparent contrast between our results and
the neurological disorders with neurofilament degeneration
observed upon SC administration of Al(lact)3 (28-30) may
simply be the result of different administration protocols.
In the case of Al(acac)3, the lack of effect may be due to
the relatively short treatment times employed so far,
together with an overwhelming cardiotoxic activity of the
drug. It is possible that much lower doses and prolonged
treatment times will lead to the production of neurologic
effects.
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